- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00796198
Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure
A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy
Hypothesis: Studies suggest that patients with low diastolic velocity and high resistivity index in the ophthalmic artery had more progressive visual fields, the investigators hypothesize therefore that addition of Cosopt to Latanoprost could improve ocular diastolic perfusion pressure (ODPP).
Objective: To evaluate the effects of Cosopt on ODPP in patients not adequately controlled with latanoprost alone.
Study Overview
Detailed Description
Fifty patients with primary open angle glaucoma (POAG) treated with Xalatan for whom the monotherapy was not sufficient to achieve the target IOP, will be included in the study. Non responders were defined when IOP was > 20 mmHg or if the IOP reduction was less than 25% from the baseline IOP. Patients will be classified as having POAG when they had a typical glaucomatous visual field and/or a typical abnormal optic nerve head, open angle at gonioscopy, IOP > 21 mmHg with no treatment and no clinically apparent secondary cause for their glaucoma (EGS guidelines).
Visual fields will be assessed by an Humphrey Field Analyzer 750 (HFA, Humphrey, Inc, CA, USA), 24-2 SITA (Swedish Interactive Threshold Algorithm) standard. A glaucomatous visual field defect was defined as: 1) three adjacent points depressed by 5 dB, with one of the points depressed by at least 10 dB; 2) two adjacent points depressed by 10 dB; or 3) a 10 dB difference across the nasal horizontal meridian in two adjacent points. None of the points could be edge points unless immediately above or below the nasal horizontal meridian. In addition, visual field testing was considered reliable only when false-negative responses were less than 30% and fixation losses were less than 20% on HFA.
The abnormal optic nerve head classification was based on the presence of an optic rim notch or of diffuse / generalized loss of optic rim tissue, vertical cup/disc diameter ratio asymmetry unexplained by side differences in optic disc size, disc haemorrhage.
In each centre, patient's recruitment will start as soon as the ethical committee will approve the protocol. Each sites will recruit 10 patients (5 + 5).
Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25), while when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25).
(EGS guidelines: Target pressure is a subjective value that none is able to assess (until now!). Efficacy of a drug: when the medication can decrease IOP as described in the phase three of their clinical trial. Not sufficient: when the medication is effective but is not able to reach the target IOP.)
Each patient will be submitted to three different visits:
- Baseline visit: Systemic Pressure, IOP, VF, HRF, Visual Acuity, ophthalmic examination with corneal central thickness (CCT)
- Visit at 1 month: Systemic Pressure , IOP, Visual Acuity, ophthalmic examination
- Visit at 3 months: Systemic Pressure, IOP , HRF, Visual Acuity, ophthalmic examination (+ CCT) ODPP will be calculated by: "systemic diastolic pressure - IOP" at each session.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Teresa Rolle, MD
- Phone Number: 00390115666032
- Email: teresa.rolle@unito.it
Study Locations
-
-
-
Bari, Italy, 70124
- University of Bari
-
Contact:
- Michele Vetrugno, MD
- Phone Number: 00 39 080 5592525
- Email: : m.vetrugno@oftalmo.uniba.it
-
Sub-Investigator:
- Michele Vetrugno, MD
-
Chieti, Italy, 66100
- University of Chieti
-
Contact:
- Marco Ciancaglini, MD
- Phone Number: 0039 0871 358410
- Email: m.ciancaglini@unich.it
-
Sub-Investigator:
- Marco Ciancaglini, MD
-
Genova, Italy, 16132
- University of Genova
-
Contact:
- Michele Iester, MD
- Phone Number: 00 39 010 3538469
- Email: iester@unige.it
-
Sub-Investigator:
- Michele Iester, MD
-
Siena, Italy, 53100
- University of Siena
-
Contact:
- Paolo Frezzotti, MD
- Phone Number: 00 39 0577 233360
- Email: frezzottip@unisi.it
-
Sub-Investigator:
- Paolo Frezzotti, MD
-
Turin, Italy, 10143
- University of Turin
-
Contact:
- Teresa Rolle, MD
- Phone Number: 00390115666032
- Email: teresa.rolle@unito.it
-
Principal Investigator:
- Teresa Rolle, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- POAG patients with a pattern deviation score (or its equivalent) ranging from 2.5 dB to 6.0 dB will be included in the study. This will ensure that patients with early/mid-stage glaucoma will be homogeneously collected; avoids advanced glaucoma in which OBF may behave as a different disease state.
- Best-corrected visual acuity will be of 0.5 or better with an ametropia <5D - Dioptric transparency, non smokers.
- Age will be between 45 and 65 years.
Exclusion Criteria:n
- Normal tension glaucoma, ocular hypertension, cardiovascular and/or metabolic diseases (known to affect blood flow, as diabetes and polycythemia)
- Visual field defects other than glaucoma; use of vasoactive and/or anti-hypertensive drugs (systemic beta-blocker), use of acetazolamide
- Hypersensibility and/or contraindications to any of the molecules studied
- Previous ocular surgery
- Pregnant or nursing women and use of one of drugs for erectile dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Xalatan+Cosopt
Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
|
Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
Xalatan ophthalmic solution one drop at 10pm
|
Active Comparator: Xalatan
when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
|
Xalatan ophthalmic solution one drop at 10pm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the effects of Cosopt on ODPP in patients not adequately controlled with latanoprost alone
Time Frame: baseline, at 1 and 3 months
|
baseline, at 1 and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the effects of Cosopt on IOP lowering in patients not adequately controlled with latanoprost alone.
Time Frame: baseline, at 1 and 3 months
|
baseline, at 1 and 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Teresa Rolle, MD, Assistent Professor, University of Turin, Department of Clinical Physiopathology, Section of Ophthalmology, Eye Clinic
- Principal Investigator: Teresa Rolle, MD, Assistent Professor, University of Turin, Department of Clinical Physiopathology-Section of Ophthalmology-Eye Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COS16102007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
iSTAR MedicalInternational Drug Development InstituteActive, not recruitingGlaucoma, Open-Angle Glaucoma EyeIndia, Panama
Clinical Trials on Xalatan+Cosopt
-
Advanced Glaucoma SpecialistsMerck Sharp & Dohme LLCUnknown
-
Alcon ResearchCompleted
-
The Catholic University of KoreaSeoul St. Mary's HospitalCompletedNormal Tension GlaucomaKorea, Republic of
-
Jadran Galenski laboratorij d.d.CompletedPrimary Open Angle Glaucoma of Both EyesRussian Federation
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOcular Hypertension | Glaucoma, Open AngleItaly, France, Greece, Sweden, Germany
-
SanofiCompletedOpen Angle Glaucoma -Ocular HypertensionUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
Nephron Pharmaceuticals CorporationCompletedPrimary Open Angle Glaucoma | Ocular HypertensionUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...WithdrawnOcular Hypertension | Glaucoma, Open-Angle
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle GlaucomaUnited States